Home

­Combined drill guide and suture passer for use in assisting repair following posterior approach total hip arthroplasty. Background:
The posterior approach to the hip for total hip replacement as well as trauma, pediatric orthopedic surgery, and tumors is the most common approach for total hip arthroplasties. However, the performance of this surgery carries risks given the lack of a devoted and standardized instrument to assist in repairing the soft tissues over the hip joint before closure, leaving room for mistakes given that the repair is operator dependent.Technology Overview:  
Upstate Medical University Orthopedic Surgeons have designed a device that features a drill guide and suture passer for posterior approach total hip arthroplasty. The device will facilitate hole drilling, as well as passing and tying sutures over the desired tissues. This will eliminate the need to visually decide where to place the drill to make the holes, as well as manually passing the suture passer through the holes to repair the tissues of the surgery for a faster, more precise, and easier procedure, which could reduce the total time of surgery, minimize risk of posterior hip dislocation and may decrease patient recovery time. https://suny.technologypublisher.com/files/sites/adobestock_272951884_(1).jpeg Advantages:  •    Sterilizable metallic surgical instrument for repetitive use.
•    Less variability of results due to user experience level.
•    Expedites closure process, minimizing post-operative risks.Intellectual Property Summary:
Patent Pending US 18/236,641Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.
 

Introducing "superGR," a novel synthetic glucocorticoid receptor fusion protein designed to enhance glucocorticoid therapy by providing ligand-independent activation and improved gene regulation for inflammatory diseases. Background:
Glucocorticoids are widely used to treat inflammatory conditions like severe alcoholic hepatitis and sepsis, but their effectiveness is often hindered by significant side effects and the development of resistance, particularly in the liver. Existing therapies rely on ligands that can cause undesired, broad activation of the glucocorticoid receptor, which restricts their clinical utility. These challenges necessitate the development of more selective and effective therapeutic approaches that can activate protective genes while minimizing harmful inflammatory responses and adverse effects.Technology Overview:  
The technology centers on the creation of "superGR," a novel fusion protein that functions as a constitutively active glucocorticoid receptor independent of ligand binding. This means it can continuously activate the receptor without needing traditional glucocorticoid molecules, which helps to avoid the use of "dirty" ligands that cause off-target effects. "SuperGR" is engineered through precise mutations that enhance its ability to selectively turn on protective genes and suppress pro-inflammatory genes more efficiently than current treatments like Dexamethasone. By addressing the core challenges of glucocorticoid resistance in the liver and unwanted side effects from conventional receptor activation, this synthetic receptor provides a more targeted and effective approach to therapy. The technology also contemplates advanced delivery mechanisms, including gene therapy vectors such as lipid nanoparticles and adeno-associated viruses, to enable efficient and focused delivery of the "superGR" gene to affected tissues. This method enhances treatment precision and reduces systemic exposure, offering significant therapeutic advantages. https://suny.technologypublisher.com/files/sites/adobestock_1714812383.jpegAdvantages:  
•    Ligand-independent activation reduces reliance on external drugs, minimizing complications related to "dirty" ligands.
•    Improved gene regulation enhances treatment efficacy by promoting protective effects and suppressing inflammation more effectively.
•    Reduced side effects compared to conventional glucocorticoid therapies due to targeted receptor modifications.
•    Potential for gene therapy-based delivery enables precise targeting and sustained therapeutic benefit. Applications:  
•    Treatment of severe alcoholic hepatitis and other inflammatory liver diseases.
•    Management of sepsis through enhanced modulation of immune responses.
•    Possible extension to other inflammatory and immune-related conditions requiring glucocorticoid therapy.
•    Use in advanced gene therapy platforms for targeted and controlled glucocorticoid receptor activation. Intellectual Property Summary:
Patent application 63/928,373 filed on 12/1/2025Stage of Development:
TRL 3Licensing Status:
This technology is available for licensing.
 

This technology is a modular, luminescent biosensor that rapidly detects DNA, RNA, small molecules, and proteins at the point of care, using a visible color change measurable by a smartphone, enabling fast, sensitive, and equipment-free diagnostics. Background:
Molecular diagnostics is a rapidly evolving field that plays a critical role in the detection and management of infectious diseases, cancer, and various other medical conditions. The ability to rapidly and accurately identify specific nucleic acids, proteins, or small molecules in patient samples is essential for timely diagnosis, treatment decisions, and disease monitoring. However, there is a growing need for diagnostic tools that can be deployed at the point-of-care—outside of centralized laboratories—to enable immediate results in clinical, field, or resource-limited settings. Such tools must be sensitive, rapid, easy to use, and cost-effective to truly democratize access to advanced healthcare diagnostics. Current diagnostic approaches, such as polymerase chain reaction (PCR), mass spectrometry, and enzyme-linked immunosorbent assays (ELISA), present significant limitations for point-of-care use. These methods typically require expensive, specialized equipment, complex sample preparation, and highly trained personnel, which restricts their use to well-equipped laboratory environments. The need for thermal cycling in PCR, for instance, adds to the complexity and power requirements, while immunoassays often involve multiple washing and incubation steps. These constraints hinder rapid bedside or field diagnostics, delay clinical decision-making, and limit accessibility in low-resource settings. Furthermore, adapting existing platforms to detect new targets often involves substantial reengineering, making it challenging to respond quickly to emerging diagnostic needs.Technology Overview:  
The technology is a modular luminescent biosensor platform, nLucAFF2, designed for rapid, sensitive, and point-of-care detection of nucleotide sequences, small molecules, and proteins. Built on an engineered nanoluciferase protein, the system produces a visible color shift from green to blue upon binding to a specific DNA sequence, a change that can be observed with the naked eye and quantified using a standard smartphone camera. This eliminates the need for expensive laboratory equipment or specialized personnel, making it highly accessible for bedside or field diagnostics. The biosensor achieves picomolar sensitivity and delivers results within 1–2 minutes, detecting analytes at concentrations as low as 0.1 nM. Its modular architecture allows it to be easily reconfigured for diverse targets: DNA hairpins or aptamers enable nucleic acid detection via a one-pot, isothermal RPA reaction, while the DNA-binding domain can be swapped for aptamers or affibodies to detect small molecules and proteins, respectively. What differentiates this technology is its combination of high sensitivity, speed, and adaptability within a user-friendly, low-cost format. Key innovations include protein engineering enhancementswhich collectively boost brightness, accelerate response, and improve detection limits compared to previous biosensors. The platform’s modularity means that new assays for different analytes can be rapidly developed with minimal changes to the core protein, streamlining the workflow for a wide range of diagnostic applications. Its smartphone-compatible readout further democratizes molecular diagnostics, enabling quantitative analysis in resource-limited settings and making it a transformative solution for infectious disease detection, cancer monitoring, therapeutic drug monitoring, and beyond. https://suny.technologypublisher.com/files/sites/adobestock_1675362203.jpegAdvantages:  
•    Rapid detection with a 1-2 minute response time, enabling timely diagnosis at the point-of-care.
•    High sensitivity with picomolar detection limits, allowing identification of low-concentration analytes.
•    Visible color change from green to blue detectable by the naked eye and quantifiable via a standard smartphone camera, eliminating the need for specialized equipment.
•    Modular design adaptable for detecting nucleic acids, small molecules, and proteins by swapping DNA-binding domains with aptamers or affibodies.
•    One-pot, isothermal recombinase polymerase amplification (RPA) simplifies the assay workflow for field and bedside use.
•    Improved brightness and sensitivity through protein engineering, enhancing detection performance over previous biosensors.
•    Low-cost, user-friendly kit format suitable for diverse applications including infectious disease diagnostics, cancer biomarker monitoring, and therapeutic drug detection.
•    Enables quantitative, smartphone-based readout, facilitating accessible and portable molecular diagnostics in resource-limited settings. Applications:  
•    Point-of-care infectious disease diagnostics
•    Cancer biomarker monitoring
•    Therapeutic drug level monitoring
•    Serotonin quantification for thrombocytopenia
•    Detection of circulating tumor DNA Intellectual Property Summary:
Patent application 63/850,804 filed on 7/25/2025Stage of Development:
•    TRL 3
•    The proof-of-concept nLucAFF2 biosensor has been fully developed.
•    Currently testing in clinical samples. Licensing Status:
This technology is available for licensing.

A new class of SHIP1 agonists that offer the potential for the development of new treatments for a variety of diseases.  Background:
An agonist is a drug or substance that binds to a cell receptor, producing the same action as the substance that would naturally bind to the receptor. Agonists form the basis for a wide variety of therapeutics. The SH-2 containing inositol 5’ polyphosphatase 1 (SHIP1) is a multifunctional protein expressed predominantly by hematopoietic cells. Over the last decade, SHIP1 has been identified as a therapeutic target due to its role in immune cells. It also plays a role in the survival of certain cancers. For example, a SHIP1-selective inhibitor has been shown to be an effective promoter of immune responses to tumor cells, a chemotherapeutic for Blymphoid cancers, hematopoietic stem cell (HSC) mobilization, and engraftment of autologous and allogeneic HSC in murine models of disease or transplantation.Technology Overview:  
This technology consists of analogs to K306, the most potent SHIP1 agonist identified to date. K306 exhibits selectivity for SHIP1 vs. the paralog enzyme SHIP2; this activation does not require the C2 domain of SHIP1 (which other known SHIP1 agonists require). Thus, K306 represents a new class of SHIP1 agonists with a novel mode of agonism. K306 can also suppress induction of inflammatory cytokines and iNOS in macrophages or microglia, but not by their SHIP1-deficient counterparts. In addition, K306 reduces TNF-α production in vivo in an LPS-induced endotoxemia assay. Finally, K306 enhances phagolysosomal degradation of synaptosomes and dead neurons by microglia, revealing a novel function for SHIP1 that might be exploited therapeutically in dementia. https://suny.technologypublisher.com/files/sites/adobestock_356174772.jpeg Advantages:  
•    Represents a new class of SHIP1 agonists with a novel mode of agonism. 
•    Suppresses induction of inflammatory cytokines and iNOS in macrophages or microglia.
•    Reduces TNF-α production in vivo in an LPS-induced endotoxemia assay. 
•    Offers a potential treatment for dementia. Applications:  
The primary application for this technology is the development of therapeutics based on SHIP1 agonists. Intellectual Property Summary:
Patent application filed on 11/15/22: 63/425,601Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential: This technology would be of interest to anyone involved in medical research and development, including:
•    Pharmaceutical and healthcare companies.
•    Hospitals.
•    Universities.
•    Medical research laboratories.­